Clinical Trial Update: A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas [Phase 2]

View source ↗

Summary

Multicenter Phase II randomized study comparing durvalumab to physician's choice chemotherapy in recurrent ovarian clear cell carcinoma; current status is not p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Clear Cell Carcinoma

Drugs mentioned

• Chemotherapy (physician's choice)
• Durvalumab (durvalumab)

Snippet

Sponsor: National University Hospital, Singapore | Conditions: Ovarian Clear Cell Carcinoma | Phase 2 | Status: UNKNOWN